MPP-Home

en / fr

Exploring The Expansion Of The Medicines Patent Pool’s Mandate To Patented Essential Medicines

A Feasibility Study Of The Public Health Needs And Potential Impact

The Medicines Patent Pool Presents New Five-Year Strategy For Improving Access To Priority Treatments In Developing Countries

Strategy and Related Feasibility Study Call for the Expansion of the MPP’s Mandate to Patented Medicines on the World Health Organization’s Model List of Essential Medicines

Annual Report

2017 was a productive year for the MPP as it continued to play a strong role in improving access to HIV, hepatitis C and tuberculosis treatments for people living in resource-limited settings. Read our 2017 Annual Report: "Partnering for Development and Delivery".

The Medicines Patent Pool Governance Board Appoints Charles Gore As New Executive Director

Former President of the World Hepatitis Alliance brings two decades of experience in public health, patient advocacy and coalition-building to the organisation.

Who We Are

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatments in low- and middle-income countries.

Vision & Mission

Our Model

Strategy

Governance & Team

Funding

Who We Work With

MedsPaL

The Medicines Patents & Licences Database

The MPP’s patents and licences database, MedsPaL, is an information resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.

Additional information and disclaimers

Transparency

All MPP licences are publicly available in their entirety on the MPP website. This is unprecedented in the pharmaceutical field.

Licence Overview

Update on Progress of Sublicensees

Forecasting

MPP in Numbers

Hover over the numbers to find out more

9 patent holders with MPP signed agreements

17 million patient-years through MPP’s generic partners from January 2012 to December 2017

25 generic manufacturers and product developers sublicensed from the MPP

17 products licensed to the MPP

130+

130+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

553

553 million dollars saved, from January 2012 to December 2017

Latest News

24 May 2018

The Medicines Patent Pool Presents New Five-Year Strategy for Improving Access to Priority Treatments in Developing Countries

Strategy and Related Feasibility Study Call for the Expansion of the MPP’s Mandate to Patented Medicines on the World Health Organization’s Model List of Essential Medicines Geneva, 24 May 2018 — The Medicines Patent Pool Foundation (MPP) released its five-year strategic plan during a side event at the 71st World Health Assembly this evening. The strategy calls for renewed efforts to reach people living with HIV, hepatitis C and tuberculosis in low- and middle-income countries (LMICs) with better-adapted, affordable medicines. Based on a feasibility study also presented at the MPP-partner event, The Path to Universal Health Coverage: Access to Affordable Treatments, the plan supports the expansion of the MPP model to other patented medicines with high medical value, starting with small molecules on the World Health Organization Model List of Essential Medicines (EML). “Over the past eight years, the MPP has made significant inroads in supporting the scale-up of new antiretrovirals, as well as curative...

22 May 2018

MPP Statement on the Global strategy and plan of action on public health, innovation and intellectual property (GSPOA) at the 71st World Health Assembly

Meeting: Seventy-first World Health Assembly (A71/1) Agenda Item: 11.6 Global strategy and plan of action on public health, innovation and intellectual property Statement: The Medicines Patent Pool welcomes the report by the Director-General on the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA). Over the past 10 years, the Global Strategy has provided a very important roadmap on strategies to promote innovation, access and technology transfer. The MPP itself is a good example of Strategy implementation. At the time of the Strategy’s adoption, a patent pool in public health to facilitate innovation and access was an interesting idea that may have seemed ambitious to many. Today, MPP, an organization funded by Unitaid, has grown to become a critical component of the international response to HIV, hepatitis and tuberculosis. The document recommends expansion of the MPP to other diseases or technologies. A focus on essential medicines represents an i...

21 May 2018

MPP Statement on Addressing the global shortage of, and access to, medicines and vaccines at the 71st World Health Assembly

Meeting: Seventy-first World Health Assembly (A71/1) Agenda Item: 11.5 Addressing the global shortage of, and access to, medicines and vaccines Statement: The Medicines Patent Pool welcomes the report by the Director-General on Addressing the Global Shortage of, and Access to, Medicines and Vaccines. We note that one of the actions considered by the Secretariat as having the greatest potential impact on access to safe, effective and quality medicines is expansion of the MPP to include all antimicrobial medicines and patented medicines from the WHO EML. The MPP was established and funded by Unitaid as a mechanism to promote innovation and access to medicines through public health-oriented licensing. It is a concrete example of progress in moving towards Universal Health Coverage by enabling over 100 countries get faster access to the latest treatments at affordable prices and in suitable formulations. Currently, the MPP holds licences on 16 medicines with 9 patent holders and 25 partner generic...

Videos

Unable to load video, please allow cookie

Endorsements

“WHO welcomes the announcement that the Medicines Patent Pool is expanding its mandate to include patented medicines on WHO’s Model List of Essential Medicines in its patent pooling and voluntary licensing initiatives. It is a welcome and significant step f...”

Unable to load twitter timeline, please allow cookie